Araştırma Makalesi
PDF EndNote BibTex RIS Kaynak Göster

The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease

Yıl 2022, Cilt 5, Sayı 2, 517 - 522, 15.03.2022
https://doi.org/10.32322/jhsm.1062603

Öz

Aim: Behçet's disease (BD) is a systemic disease, with still unknown etiology and pathogenesis and varying disease presentations, characterized by recurrent oral aphthae, followed by genital ulcers, arthritis, variable skin and ocular lesions, gastrointestinal and central nervous system involvement, as well as, vascular disease. Colchicine is one of the oldest remedies still in use today. The study aimed to investigate the effect of colchicine on levels of the complete blood cell count-based parameters in BD. Material and Method: A total of 117 (participants 60 healthy control and 57 patients with BD) were recruited from the rheumatology department in a single-center case-control study. The laboratory data were obtained from the electronic registration database. Laboratory findings of patients and healthy controls were evaluated. In addition, patients with BD were evaluated for these parameters before colchicine therapy and after 3-month from the beginning of colchicine treatment. Results: The levels of inflammatory markers such as neutrophil count, neutrophil to lymphocyte ratio (NLR), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and systemic immune-inflammation index (SII), significantly higher than the control group before treatment, decreased to similar levels with the control group in the third month of colchicine use. However, red blood cell distribution width (RDW), mean platelet volume (MPV), and plateletcrit (PCT) were still statistically significantly different from the control group in BD patients. Conclusion: SII, CRP, ESR, and NLR are useful parameters to evaluate the colchicine response of patients with mucocutaneous BD.

Kaynakça

  • Kiafar M, Faezi ST, Kasaeian A, et al. Diagnosis of Behcet's disease: clinical characteristics, diagnostic criteria, and differential diagnoses. BMC Rheumatol 2021; 5: 2.
  • Mattioli I, Bettiol A, Saruhan-Direskeneli G, Direskeneli H, Emmi G. Pathogenesis of Behçet's syndrome: genetic, environmental and immunological factors. Front Med (Lausanne) 2021; 8: 713052.
  • Criteria for diagnosis of Behçet's disease. International study group for Behçet's disease. Lancet 1990; 335: 1078-80.
  • Chen J, Yao X. A contemporary review of Behcet's syndrome. Clin Rev Allergy Immunol 2021; 61: 363-76.
  • Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 2015; 11: 1781–94.
  • Tezcan D, Körez MK, Gülcemal S, Hakbilen S, Akdağ T, Yılmaz S. Evaluation of diagnostic performance of hematological parameters in Behçet's disease. Int J Clin Pract 2021; 10: e14638.
  • Gheita TA, Sakr BR, Rabea RE, Abd ElHamid SM. Value of hematological indices versus VEGF as biomarkers of activity in Behçet's disease. Clin Rheumatol 2019; 38: 2201-10.
  • Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal 2021; 35: e23964.
  • Fest J, Ruiter R, Mulder M, et al. The systemic immune‐inflammation index is associated with an increased risk of incident cancer‐a population‐based cohort study. Int J Cancer 2020; 146: 692‐8.
  • Safi R, Kallas R, Bardawil T, et al. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease. J Dermatol Sci 2018; 92: 143–50.
  • Ataş H, Cemil BC, Canpolat F, Gönül M. The effect of colchicine on mean platelet volume in Behcet's disease. Ann Clin Lab Sci 2015; 45: 545-9.
  • Yolbas S, Yildirim A, Gozel N, Uz B, Koca SS. Hematological ındices may be useful in the diagnosis of systemic lupus erythematosus and in determining disease activity in Behçet's disease. Med Princ Pract 2016; 25: 510-6.
  • Erden F, Karagoz H, Avci A, et al. Which one is best? Platelet/lymphocyte ratio, neutrophil/lymphocyte ratio, or both in determining deep venous thrombosis in Behcet's disease? Biomed Res-India 2017; 28: 5304-9.
  • Lee YH, Song GG. Neutrophil-to-lymphocyte ratio, mean platelet volume, and platelet-to-lymphocyte ratio in Behçet's disease and their correlation with disease activity: ameta-analysis. Int J Rheum Dis 2018; 21: 2180-7.
  • Aksoy ŞN, Savaş E, Sucu M, Kisacik B, Kul S, Zengin O. Association between red blood cell distribution width and disease activity in patients with Behçet's disease. J Int Med Res 2015; 43: 765-73.
  • Djaballah-Ider F, Touil-Boukoffa C. Effect of combined colchicine-corticosteroid treatment on neutrophil/lymphocyte ratio: a predictive marker in Behçet disease activity. Inflammopharmacol 2020; 28: 819–29.
  • Hammad M, Shehata OZ, Abdel-Latif SM, El-Din AMM. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet's disease: which and when to use? Clin Rheumatol 2018; 37: 2811-7.
  • Avci A, Avci D, Erden F, et al. Can we use the neutrophil-to-lymphocyte ratio platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet's disease? Ther Clin Risk Manag 2017; 13: 881-6.
  • Shadmanfar S, Masoumi M, Davatchi F, et al. Correlation of clinical signs and symptoms of Behçet's disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR). Immunol Res 2021; 69: 363-71.
  • Cantarini L, Pucino V, Vitale A, et al. Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with epidemiological profile, disease activity, and therapeutic regimens. Clin Exp Immunol 2016; 184: 197-207.
  • Ünlü M, Arslan Z. The relation between neutrophil-lymphocyte ratio and endothelial dysfunction. Angiology 2015; 66: 694.
  • Tanacan E, Dincer D, Erdogan FG, Gurler A. A cutoff value for the Systemic Immune-Inflammation Index in determining activity of Behçet disease. Clin Exp Dermatol 2021; 46: 286-91.
  • Kim Y, Choi H, Jung SM, et al. Systemic immune‐inflammation index could estimate the cross‐sectional high activity and the poor outcomes in immunosuppressive drug‐naïve patients with antineutrophil cytoplasmic antibody‐associated vasculitis. Nephrol (Carlton) 2019; 24: 711‐7.
  • Velazquez S, Madurga R, Castellano JM, et al. Hemogram-derived ratios as prognostic markers of ICU admission in COVID-19. BMC Emerg Med 2021; 21: 89.
  • Kim JW, Jung JY, Suh CH, Kim HA. Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still's disease. Clin Rheumatol 2021; 40: 661-8.
  • Ataş H, Canpolat F, Eskioglu F. Evaluation of mean platelet volume in patients with Behcet's disease as an indicator of vascular thrombosis. Arch Iran Med 2018; 21: 234-9.
  • Lippi G, Buonocore R, Cervellin G. The mean platelet volume is de- creased in patients diagnosed with venous thromboembolism in the emergency department. Semin Thromb Hemost 2016; 42: 632-5.
  • Masoumi M, Shadmanfar S, Davatchi F, et al. Correlation of clinical signs and symptoms of Behçet's disease with mean platelet volume (MPV) and red cell distribution width (RDW). Orphanet J Rare Dis 2020; 15: 297.
  • Vázquez-Santiago M, Vilalta N, Ziyatdinov A, et al. Platelet count and plateletcrit are associated with an increased risk of venous thrombosis in females. Results from the RETROVE study. Thromb Res 2017; 157: 162-4.
  • Ergelen M, Uyarel H. Plateletcrit: a novel prognostic marker for acute coronary syndrome. Int J Cardiol 2014; 177: 161.
  • Tezcan D, Özer H, Gülcemal S, et al. Diagnostic performance of lower extremity venous wall thickness and laboratory findings in the diagnosis of the Behçet disease. J Clin Rheumatol 2022; 28: e521-e527.
  • Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C. Behçet's syndrome as a model of thrombo-ınflammation: the role of neutrophils. Front Immunol 2019; 10: 1085.

Yıl 2022, Cilt 5, Sayı 2, 517 - 522, 15.03.2022
https://doi.org/10.32322/jhsm.1062603

Öz

Kaynakça

  • Kiafar M, Faezi ST, Kasaeian A, et al. Diagnosis of Behcet's disease: clinical characteristics, diagnostic criteria, and differential diagnoses. BMC Rheumatol 2021; 5: 2.
  • Mattioli I, Bettiol A, Saruhan-Direskeneli G, Direskeneli H, Emmi G. Pathogenesis of Behçet's syndrome: genetic, environmental and immunological factors. Front Med (Lausanne) 2021; 8: 713052.
  • Criteria for diagnosis of Behçet's disease. International study group for Behçet's disease. Lancet 1990; 335: 1078-80.
  • Chen J, Yao X. A contemporary review of Behcet's syndrome. Clin Rev Allergy Immunol 2021; 61: 363-76.
  • Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 2015; 11: 1781–94.
  • Tezcan D, Körez MK, Gülcemal S, Hakbilen S, Akdağ T, Yılmaz S. Evaluation of diagnostic performance of hematological parameters in Behçet's disease. Int J Clin Pract 2021; 10: e14638.
  • Gheita TA, Sakr BR, Rabea RE, Abd ElHamid SM. Value of hematological indices versus VEGF as biomarkers of activity in Behçet's disease. Clin Rheumatol 2019; 38: 2201-10.
  • Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal 2021; 35: e23964.
  • Fest J, Ruiter R, Mulder M, et al. The systemic immune‐inflammation index is associated with an increased risk of incident cancer‐a population‐based cohort study. Int J Cancer 2020; 146: 692‐8.
  • Safi R, Kallas R, Bardawil T, et al. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease. J Dermatol Sci 2018; 92: 143–50.
  • Ataş H, Cemil BC, Canpolat F, Gönül M. The effect of colchicine on mean platelet volume in Behcet's disease. Ann Clin Lab Sci 2015; 45: 545-9.
  • Yolbas S, Yildirim A, Gozel N, Uz B, Koca SS. Hematological ındices may be useful in the diagnosis of systemic lupus erythematosus and in determining disease activity in Behçet's disease. Med Princ Pract 2016; 25: 510-6.
  • Erden F, Karagoz H, Avci A, et al. Which one is best? Platelet/lymphocyte ratio, neutrophil/lymphocyte ratio, or both in determining deep venous thrombosis in Behcet's disease? Biomed Res-India 2017; 28: 5304-9.
  • Lee YH, Song GG. Neutrophil-to-lymphocyte ratio, mean platelet volume, and platelet-to-lymphocyte ratio in Behçet's disease and their correlation with disease activity: ameta-analysis. Int J Rheum Dis 2018; 21: 2180-7.
  • Aksoy ŞN, Savaş E, Sucu M, Kisacik B, Kul S, Zengin O. Association between red blood cell distribution width and disease activity in patients with Behçet's disease. J Int Med Res 2015; 43: 765-73.
  • Djaballah-Ider F, Touil-Boukoffa C. Effect of combined colchicine-corticosteroid treatment on neutrophil/lymphocyte ratio: a predictive marker in Behçet disease activity. Inflammopharmacol 2020; 28: 819–29.
  • Hammad M, Shehata OZ, Abdel-Latif SM, El-Din AMM. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet's disease: which and when to use? Clin Rheumatol 2018; 37: 2811-7.
  • Avci A, Avci D, Erden F, et al. Can we use the neutrophil-to-lymphocyte ratio platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet's disease? Ther Clin Risk Manag 2017; 13: 881-6.
  • Shadmanfar S, Masoumi M, Davatchi F, et al. Correlation of clinical signs and symptoms of Behçet's disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR). Immunol Res 2021; 69: 363-71.
  • Cantarini L, Pucino V, Vitale A, et al. Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with epidemiological profile, disease activity, and therapeutic regimens. Clin Exp Immunol 2016; 184: 197-207.
  • Ünlü M, Arslan Z. The relation between neutrophil-lymphocyte ratio and endothelial dysfunction. Angiology 2015; 66: 694.
  • Tanacan E, Dincer D, Erdogan FG, Gurler A. A cutoff value for the Systemic Immune-Inflammation Index in determining activity of Behçet disease. Clin Exp Dermatol 2021; 46: 286-91.
  • Kim Y, Choi H, Jung SM, et al. Systemic immune‐inflammation index could estimate the cross‐sectional high activity and the poor outcomes in immunosuppressive drug‐naïve patients with antineutrophil cytoplasmic antibody‐associated vasculitis. Nephrol (Carlton) 2019; 24: 711‐7.
  • Velazquez S, Madurga R, Castellano JM, et al. Hemogram-derived ratios as prognostic markers of ICU admission in COVID-19. BMC Emerg Med 2021; 21: 89.
  • Kim JW, Jung JY, Suh CH, Kim HA. Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still's disease. Clin Rheumatol 2021; 40: 661-8.
  • Ataş H, Canpolat F, Eskioglu F. Evaluation of mean platelet volume in patients with Behcet's disease as an indicator of vascular thrombosis. Arch Iran Med 2018; 21: 234-9.
  • Lippi G, Buonocore R, Cervellin G. The mean platelet volume is de- creased in patients diagnosed with venous thromboembolism in the emergency department. Semin Thromb Hemost 2016; 42: 632-5.
  • Masoumi M, Shadmanfar S, Davatchi F, et al. Correlation of clinical signs and symptoms of Behçet's disease with mean platelet volume (MPV) and red cell distribution width (RDW). Orphanet J Rare Dis 2020; 15: 297.
  • Vázquez-Santiago M, Vilalta N, Ziyatdinov A, et al. Platelet count and plateletcrit are associated with an increased risk of venous thrombosis in females. Results from the RETROVE study. Thromb Res 2017; 157: 162-4.
  • Ergelen M, Uyarel H. Plateletcrit: a novel prognostic marker for acute coronary syndrome. Int J Cardiol 2014; 177: 161.
  • Tezcan D, Özer H, Gülcemal S, et al. Diagnostic performance of lower extremity venous wall thickness and laboratory findings in the diagnosis of the Behçet disease. J Clin Rheumatol 2022; 28: e521-e527.
  • Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C. Behçet's syndrome as a model of thrombo-ınflammation: the role of neutrophils. Front Immunol 2019; 10: 1085.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Orijinal Makale
Yazarlar

Dilek TEZCAN> (Sorumlu Yazar)
SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, GÜLHANE TIP FAKÜLTESİ, GÜLHANE TIP PR. (ANKARA)
0000-0002-8295-9770
Türkiye


Çağrı TURAN>
Medical Park Ankara Hospital
0000-0002-6111-4314
Türkiye


Sema YİLMAZ>
SELÇUK ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0001-5076-1500
Türkiye

Destekleyen Kurum NONE
Proje Numarası NONE
Teşekkür We acknowledge our patients for the consent to publish this research for teaching medical professionals to help their patients better.
Yayımlanma Tarihi 15 Mart 2022
Yayınlandığı Sayı Yıl 2022, Cilt 5, Sayı 2

Kaynak Göster

Bibtex @araştırma makalesi { jhsm1062603, journal = {Journal of Health Sciences and Medicine}, eissn = {2636-8579}, address = {Kırıkkale Üniversitesi Tıp Fakültesi / İç Hastalıkları Anabilim Dalı}, publisher = {MediHealth Academy Yayıncılık}, year = {2022}, volume = {5}, number = {2}, pages = {517 - 522}, doi = {10.32322/jhsm.1062603}, title = {The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease}, key = {cite}, author = {Tezcan, Dilek and Turan, Çağrı and Yilmaz, Sema} }
APA Tezcan, D. , Turan, Ç. & Yilmaz, S. (2022). The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease . Journal of Health Sciences and Medicine , 5 (2) , 517-522 . DOI: 10.32322/jhsm.1062603
MLA Tezcan, D. , Turan, Ç. , Yilmaz, S. "The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease" . Journal of Health Sciences and Medicine 5 (2022 ): 517-522 <https://dergipark.org.tr/tr/pub/jhsm/issue/68828/1062603>
Chicago Tezcan, D. , Turan, Ç. , Yilmaz, S. "The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease". Journal of Health Sciences and Medicine 5 (2022 ): 517-522
RIS TY - JOUR T1 - The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease AU - DilekTezcan, ÇağrıTuran, SemaYilmaz Y1 - 2022 PY - 2022 N1 - doi: 10.32322/jhsm.1062603 DO - 10.32322/jhsm.1062603 T2 - Journal of Health Sciences and Medicine JF - Journal JO - JOR SP - 517 EP - 522 VL - 5 IS - 2 SN - -2636-8579 M3 - doi: 10.32322/jhsm.1062603 UR - https://doi.org/10.32322/jhsm.1062603 Y2 - 2022 ER -
EndNote %0 Journal of Health Sciences and Medicine The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease %A Dilek Tezcan , Çağrı Turan , Sema Yilmaz %T The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease %D 2022 %J Journal of Health Sciences and Medicine %P -2636-8579 %V 5 %N 2 %R doi: 10.32322/jhsm.1062603 %U 10.32322/jhsm.1062603
ISNAD Tezcan, Dilek , Turan, Çağrı , Yilmaz, Sema . "The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease". Journal of Health Sciences and Medicine 5 / 2 (Mart 2022): 517-522 . https://doi.org/10.32322/jhsm.1062603
AMA Tezcan D. , Turan Ç. , Yilmaz S. The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease. J Health Sci Med /JHSM /jhsm. 2022; 5(2): 517-522.
Vancouver Tezcan D. , Turan Ç. , Yilmaz S. The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease. Journal of Health Sciences and Medicine. 2022; 5(2): 517-522.
IEEE D. Tezcan , Ç. Turan ve S. Yilmaz , "The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease", Journal of Health Sciences and Medicine, c. 5, sayı. 2, ss. 517-522, Mar. 2022, doi:10.32322/jhsm.1062603

Üniversitelerarası Kurul (UAK) Eşdeğerliği: Ulakbim TR Dizin ve 1b [Uluslararası alan indekslerine göre taranan dergilerde yayınlanan özgün araştırma makalesi (1a'da belirtilenler dışındaki dizinlerde yer alır) - 10 PUAN]. Dahil olduğumuz İndeksler (Dizinler) ve Platformlar sayfanın en altındadır.

Not:
Dergimiz WOS indeksli değildir ve bu nedenle Q olarak sınıflandırılmamıştır.

Yüksek Öğretim Kurumu (YÖK) kriterlerine göre yağmacı/şüpheli dergiler hakkındaki kararları ile yazar aydınlatma metni ve dergi ücretlendirme politikasını tarayıcınızdan indirebilirsiniz. https://dergipark.org.tr/tr/journal/2316/file/4905/show 


Dergi Dizin ve Platformları

Dizinler; ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, vs.

Platformlar; Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons vs.